39results about How to "Improve pharmaceutical properties" patented technology

A novel crystalline form of sitagliptin sulfate is provided. In addition, a method for obtaining the crystalline form, pharmaceutical compositions comprising the novel crystalline form and the crystalline form for use as a medicament are provided.

The invention discloses a pyrimidine compound of a structural formula A. The structural formula A is shown below. The pyrimidine compound can be used for preparing medicaments for treating diseases associated with vasculogenesis, in particular medicaments for treating tumor, age-related macular degeneration or autoimmune diseases.

The invention belongs to the field of chemical pharmacy and in particular relates to a cisatracurium besilate composition for injection and a preparation method and application thereof. The cisatracurium besilate composition for injection comprises cisatracurium besilate, sodium chloride, glucose and a pH regulator, wherein cisatracurium besilate takes cisatracurium as an active ingredient, and cisatracurium, sodium chloride and glucose are combined according to a certain ratio. The cisatracurium besilate composition for injection disclosed by the invention is simple in composition, convenient to operate, simple in freeze-drying process, controllable in quality, low in content of product related substances, high in reproducibility and convenient to popularize and utilize.

The invention discloses a lurasidone medicine composition and a preparation method. The lurasidone medicine composition comprises the lurasidone shown in the formula (I), sugar alcohol, disintegrant, adhesive, surfactant and optional water-insoluble filler. In the lurasidone medicine composition disclosed by the invention, the contact angle between the surface and water is not greater than 95 degrees. The preparation of lurasidone (particularly tablet) has good release performance and mechanical performance.

The invention relates to sugar-free lysine zinc gluconate granules and a quality detection method thereof, specifically belongs to the technical field of medicine, relates to a composition for supplementing lysine and zinc, especially zinc gluconate, in particular relates to granules for supplementing lysine and zinc, especially zinc gluconate, and more in particular relates to sugar-free lysine zinc gluconate granules for supplementing lysine and zinc, especially zinc gluconate. The invention also relates to a method for performing quality detection on the sugar-free lysine zinc gluconate granules. The lysine zinc gluconate granules are a mineral substance type OTC medicine. The sugar-free lysine zinc gluconate granules are clinically used for preventing and treating growth retardation, malnutrition, anorexia and the like of children and adolescents due to lack of lysine and zinc. The lysine contained in the lysine zinc gluconate granules is one of essential amino acids for maintaining the nitrogen balance of a human body and has the effect of promoting the growth of the human body; zinc is an important component for a plurality of enzymes in vivo, and has the effects of promoting growth and development and improving gustation.

The present invention relates to an inclusion state puerarin/cyclodextrin composition in which the mole ratio of cyclodextrin and puerarin is 1-5:1. the described cyclodextrin can be beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin or sulfo-bulyl-beta-cyclodextrin or their mixture. Besides, said invention also provides its preparation method and concrete steps.

The invention relates to a pitavastatin calcium tablet pharmaceutical composition and a dry or wet preparation method thereof. Specifically, one aspect of the invention relates to a pitavastatin calcium tablet which comprises a tablet core and a coating layer, wherein the tablet core comprises 1 part of pitavastatin calcium, 40-120 parts of a filling agent, 4-20 parts of a disintegrating agent, 0.5-5 parts of an adhesive, 0.5-5 parts of a stabilizer and 0.3-3 parts of a lubricating agent. The tablet core can be made from lactose, microcrystalline cellulose, tricalcium phosphate, low substituted hydroxypropy cellulose, crospovidone, sodium carboxymethyl starch, aluminum-magnesium silicate, aluminum-magnesium metasilicate, hydroxypropyl methylcellulose, magnesium stearate and other excipients and combinations thereof. The tablet core can be prepared through a dry granulation tabletting process or a wet granulation tabletting process. The invention further relates to a preparation method of pitavastatin calcium tablets and application thereof in preparation of drugs for treating and/or preventing hypercholesteremia or familial hypercholesterolemia. The tablet pharmaceutical composition disclosed by the invention has excellent properties shown in the specification.

The present invention relates to the technical field of medicine, specifically to a composition, which contains a compound (a), a pharmaceutically acceptable salt, an ester, a solvate or a stereoisomer thereof, and at least a carbapenem antibiotic or a derivative thereof, wherein the compound (a) has a structure represented by a formula (I) defined in the specification. The invention further relates to uses of the composition in preparation of drugs for prevention and/or treatment of infectious diseases caused by bacteria, wherein preferably the bacteria have drug resistance caused by beta-lactamase.

The invention relates to a sugar-free lysine and gluconic acid zinc granule composition and a preparation method thereof, belongs to the technical field of the medicine, relates to a composition for supplementing lysine and zinc, and especially gluconic acid zinc, in particular relates to a granule for supplementing the lysine and the zinc, and especially the gluconic acid zinc, and more specifically relates to a sugar-free granule for supplementing the lysine and the zinc, and especially the gluconic acid zinc. The invention also relates to a method for preparing the composition. The lysine and gluconic acid zinc granule is a mineral substance type nonprescription drug. The lysine and gluconic acid zinc granule is clinically used for preventing and treating growth retardation, malnutrition, anorexia and the like of children and adolescents for lack of lysine and zinc. The lysine contained in the lysine and gluconic acid zinc granules is one of the necessary amino acids for maintaining the nitrogen balance of a human body and is capable of promoting the growth of the human body; the zinc is an important component of a plurality of enzymes in vivo and is capable of promoting the growth and improving the sense of taste.

The invention relates to preparation of a powder injection pharmaceutical composition from high-purity papaverine hydrochloride, in particular to a preparation method of papaverine hydrochloride. Themethod comprises the following steps of: heating 3, 4-dimethoxy-beta-phenyl-ethylamine and 3, 4-dimethoxy-phenyl-acetic acid to melting, and then carrying out reaction in a mixture of benzene and chlorethoxyfos to obtain 6, 7, 3', 4'-tetramethoxy-1-benzyl-dihydro-isoquinoline hydrochloride; then dissolving the wet product in tetrahydronaphthalene after the wet product becomes free alkali, and carrying out dehydrogenation reaction at 180DEG C in the presence of a Raney nickel catalyst; after dehydrogenation is finished, directly filtering the tetrahydronaphthalene reaction mixture from the Raney nickel catalyst into a mixture of a hydrochloric acid aqueous solution and methanol; filtering out precipitates, and performing recrystallizing from the ethanol-water solution in an inert gas environment to obtain off-white 6, 7, 3', 4'-tetramethoxy-1-benzyl isoquinoline hydrochloride, namely papaverine hydrochloride. The invention also relates to a papaverine hydrochloride powder injection pharmaceutical composition, and a preparation method and a quality detection method thereof. The invention achieves excellent technical effects as described in the specification.

The invention relates to the use of alcladinine in the preparation of medicines for diseases related to GP80, especially for liver cancer related to GP80, alcladine has shown good pharmaceutical effects. The present invention provides a further research direction for the targeting of alcradine in the treatment of cancer.

The invention relates to application of Icaritin in preparation of drugs for curing GP130 related diseases, particularly GP130 related liver cancer, and the Icaritin shows excellent pharmaceutical effect. According to the application of the Icaritin in preparation of the drugs for curing the GP130 related diseases, research direction is further provided for Icaritin in targeting of cancer curing.

The invention relates to a pharmaceutical composition of dexamethasone sodium phosphate for injection and a preparation method of the pharmaceutical composition, and in particular relates to a freeze-dried powder injection pharmaceutical composition of dexamethasone sodium phosphate. The freeze-dried powder injection pharmaceutical composition comprises dexamethasone sodium phosphate and a freeze-dried excipient which is selected from one or more of mannitol, glycine, lactose and saccharose, wherein the weight ratio of dexamethasone sodium phosphate to mannitol is 1:(1-50). The freeze-dried powder injection pharmaceutical composition of dexamethasone sodium phosphate disclosed by the invention is applicable to treatment of irritability and autoimmunity-related diseases, is particularly used for connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, acute leukemia and the like, and also can be used for comprehensive treatment on serious infection and poisoning, and malignant lymphoma. The freeze-dried powder injection pharmaceutical composition of dexamethasone sodium phosphate disclosed by the invention has excellent pharmaceutical property as described in the specification.

The invention is applicable to the technical field of processing of traditional Chinese medicine decoction pieces, and provides a processing method of ginger processed pinellia, which comprises the following steps: adding water into dried ginger, decocting twice, respectively collecting and combining a first extracting solution and a second extracting solution to obtain a total extracting solution, adding alum into the total extracting solution, stirring and dissolving to obtain a ginger decoction and alum solution, and drying to obtain the ginger processed pinellia; soaking pinellia ternate in the ginger decoction and the alum solution, taking out, slicing, steaming and drying to obtain ginger pinellia ternate; processing the rhizoma pinelliae by adopting the dried ginger, and the matching of auxiliary materials, a soaking process and a process of slicing first and then steaming are optimized, so that the content of the obtained extract is remarkably increased and reaches 21.82%, the contrast amplification is 29.97%, and the limit of alum is 5.735%; the dried ginger is small in dosage, easy to store and suitable for large-scale production; the prepared ginger processed pinellia is brown to brown and meets the regulations of Chinese Pharmacopoeia; the whole process is few in procedures, simple in equipment and low in energy consumption, water treatment time is shortened, effective components are reserved as far as possible, alum is properly reserved, and the medicinal effect of ginger processed pinellia is improved.

The present invention relates to an orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride. It specifically relates to an orally disintegrating tablet, which is a tablet compressed by a tableting process; the tablet includes a tablet matrix composed of various auxiliary materials, and two One kind of coated pellets; the two kinds of coated pellets respectively include a pellet core containing two different active ingredients and at least one layer of coating covering the surface of the pellet core. The invention also relates to a preparation method of the orally disintegrating tablet and its corresponding use. The orally disintegrating tablet of the present invention exhibits the excellent technical effect described in the description of the present invention.

The invention relates to the technical field of medicines, in particular to a medicine product. The medicine product comprises a compound (a), or salt or ester or a solvent compound, which can be pharmaceutically accepted, of the compound (a), or stereoisomer of the compound (a), and one or more beta-lactam antibiotics or derivatives of the beta-lactam antibiotics, wherein the compound (a) has a structure shown in a formula (I) (please see the specifications for the formula (I)). Meanwhile, the invention further relates to application of the medicine product to preparation of medicines for treating and/or preventing bacterial infectious diseases, preferably, bacteria have medicine resistance caused by the beta-lactamase.

The invention relates to a pharmaceutical composition and a preparation method of clindamycin phosphate injection. Specifically, the present invention belongs to the field of medical technology, and relates to a pharmaceutical composition for injection and a preparation process thereof, in particular to a pharmaceutical composition for clindamycin injection and a preparation method thereof, more particularly to a Clindamycin phosphate injection pharmaceutical composition and its preparation method. In one embodiment, the pharmaceutical composition of clindamycin phosphate injection of the present invention comprises clindamycin phosphate, complexing agent, bacteriostat, acid-base regulator and water for injection. The pharmaceutical composition of clindamycin phosphate injection for injection of the present invention has remarkable and excellent pharmaceutical properties.